Dual-Targeted Therapy with Risankizumab and Upadacitinib in Medically Complex Crohn’s Disease
Clicks: 3
ID: 316089
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #26 of 38 articles by views in Crohn s & Colitis 360
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Lay Summary This study presents real-world observational data of the combination of risankizumab and upadacitinib and demonstrates the safety and effectiveness of this unique combination strategy for the treatment of medically complex Crohn’s disease.
| Reference Key |
openalex_W7163743476
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Evan N. Fear, Benjamin D McDonald, Megan S. Kennedy, Alex Mathew, Ross McMillan, Zachary D. Fine, Alexandra McDermott, D Y Choi, Amelia Kellar, David T Rubin |
| Journal | Crohn s & Colitis 360 |
| Year | 2026 |
| DOI |
10.1093/crocol/otag049
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.